Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human TRIP6 Antikörper:
anti-Mouse (Murine) TRIP6 Antikörper:
anti-Rat (Rattus) TRIP6 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal TRIP6 Primary Antibody für WB - ABIN256662
Li, Bin, Li, Liu, Chen, Zhai, Shu: TRIP6 is a RIP2-associated common signaling component of multiple NF-kappaB activation pathways. in Journal of cell science 2005
Show all 5 Pubmed References
Human Monoclonal TRIP6 Primary Antibody für FACS, ELISA - ABIN1098130
Willier, Butt, Richter, Burdach, Grunewald: Defining the role of TRIP6 in cell physiology and cancer. in Biology of the cell / under the auspices of the European Cell Biology Organization 2011
Show all 2 Pubmed References
Human Polyclonal TRIP6 Primary Antibody für ELISA, WB - ABIN563258
McMichael, Meyer, Lee: c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation. in The Journal of biological chemistry 2010
Cow (Bovine) Polyclonal TRIP6 Primary Antibody für WB - ABIN2784547
Johnson, Bai, Smith, Patel, Wang: Single-molecule studies reveal dynamics of DNA unwinding by the ring-shaped T7 helicase. in Cell 2007
Show all 2 Pubmed References
Cow (Bovine) Polyclonal TRIP6 Primary Antibody für WB - ABIN2784548
Bai, Ohsugi, Abe, Yamamoto: ZRP-1 controls Rho GTPase-mediated actin reorganization by localizing at cell-matrix and cell-cell adhesions. in Journal of cell science 2007
Show all 2 Pubmed References
Human Polyclonal TRIP6 Primary Antibody für ELISA, IP - ABIN4362555
Shanmugarajan, Kawanabe, Koide, Tsuruga, Arroyo, Key, Reddy: IL-12 stimulates the osteoclast inhibitory peptide-1 (OIP-1/hSca) gene expression in CD4+ T cells. in Journal of cellular biochemistry 2009
Taken together, these findings showed that TRIP6 plays an important role in promoting HCC (zeige FAM126A Antikörper) cells proliferation and may serve as a novel prognostic biomarker and therapeutic target in HCC (zeige FAM126A Antikörper).
TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance via regulating nuclear p27(Kip1 (zeige CDKN1B Antikörper)) expression in non-Hodgkin's lymphoma
the Trip6-GRIP1-myosin VI interaction and its regulation on F-actin network play a significant role in dendritic morphogenesis
TRIP6 overexpression promotes migration, invasion, and clonogenicity of Ewing's sarcoma cells
TRIP6 is involved in the regulation of nasopharyngeal carcinoma cell motility, and phosphorylation of tyrosine 55 residue plays an important regulatory role for this event
TRIP6 also promotes serum-induced reduction of nuclear p27(KIP1 (zeige CDKN1B Antikörper)) expression levels.
High TRIP6 expression is associated with malignant pleural mesothelioma.
TRIP6 is a nucleocytoplasmatic shuttle protein essential for the coordination of focal adhesion dynamics and transcriptional responses in lysophosphosphatidic (LPA (zeige APOA Antikörper)) and NF-kappaB (zeige NFKB1 Antikörper) signaling.
TRIP6 is an adaptor protein that regulates cell motility, antiapoptotic signaling and transcriptional activity. (Review)
TRIP6 promotes Fas (zeige FAS Antikörper)-mediated cell migration in apoptosis-resistant glioma cells. This effect is regulated via the Src (zeige SRC Antikörper)-dependent phosphorylation of TRIP6 at Tyr (zeige TYR Antikörper)-55.
Data report that nTRIP6 acts as a co-repressor for MEF2C (zeige MEF2C Antikörper) in myoblasts. nTRIP6 interacts via its N-terminal pre-LIM (zeige PDLIM5 Antikörper) region with MEF2C (zeige MEF2C Antikörper) in the nucleus of myoblasts, is recruited together with MEF2C (zeige MEF2C Antikörper) to the regulatory regions of MEF2C (zeige MEF2C Antikörper) target genes and represses their expression.
Our data suggest that TRIP6 regulates neural stem cell maintenance and it may be a new marker for neural stem cells.
Data show that OIP-1 (Trip6) is an important physiologic regulator of osteoclast development and may have therapeutic utility for bone diseases with high bone turnover.
TRIP6 is a critical downstream regulator of c-Src signaling and its phosphorylation is permissive for its presence in the sealing zone where it plays a positive role in osteoclast bone resorptive capacity
TRIP6 functions at a point of convergence between the activated LPA(2 (zeige LPAR2 Antikörper)) receptor and downstream signals involved in cell adhesion and migration
TRIP6 in lysophosphatidic acid signaling is regulated by c-Src (zeige SRC Antikörper)-mediated phosphorylation of TRIP6 at the Tyr (zeige TYR Antikörper)-55 residue.
nTrip6 interacts only with Fos family members. Consequently, nTrip6 is a selective coactivator for AP-1 dimers containing Fos. nTrip6 also assembles activated GR to c-Jun:c-Fos-driven promoters.
This gene is a member of the zyxin family and encodes a protein with three LIM zinc-binding domains. This protein localizes to focal adhesion sites and along actin stress fibers. Recruitment of this protein to the plasma membrane occurs in a lysophosphatidic acid (LPA)-dependent manner and it regulates LPA-induced cell migration. Alternatively spliced variants which encode different protein isoforms have been described\; however, not all variants have been fully characterized.
thyroid hormone receptor interactor 6
, thyroid receptor-interacting protein 6-like
, thyroid receptor-interacting protein 6
, OPA-interacting protein 1
, TR-interacting protein 6
, thyroid hormone receptor interacting protein 6
, zyxin related protein 1
, zyxin-related protein 1